[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643248":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":25,"responsibleParty":32,"collaborators":25,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":25,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":25,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":25,"overallStatus":53,"whyStopped":25,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":25},{"fullName":5,"class":6},"Hematology department of the 920th hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"2-week VACAG regimen for newly diagnosed acute myeloid leukemia","EXPERIMENTAL","Specific Medication for the 2-week VACAG regimen Protocol:\n\nAzacitidine: 75 mg\u002Fm² on days 1-7 by subcutaneous injection, Venetoclax: 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-14, oral, Arubicin: 12-14 mg\u002Fm² on days 1, 3, 5, and 7 (IV infusion), Cytarabine: 10 mg\u002Fm² every 12 hours on days 1-7, subcutaneous injection, Recombinant human granulocyte colony-stimulating factor: 5 μg\u002Fkg on days 0-8; discontinue if WBC \\> 20 × 10⁹\u002FL;",[13],"Drug: Venetoclax,Azacitidine,Arubicin,Cytarabine,G-CSF.",{"label":15,"type":16,"description":17,"interventionNames":18},"3-week VACAG regimen for newly diagnosed acute myeloid leukemia","ACTIVE_COMPARATOR","Specific Medication for the 3-week VACAG regimen Protocol:\n\nAzacitidine: 75 mg\u002Fm² on days 1-7 by subcutaneous injection, Venetoclax: 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-21, oral, Arubicin: 12-14 mg\u002Fm² on days 1, 3, 5, and 7 (IV infusion), Cytarabine: 10 mg\u002Fm² every 12 hours on days 1-7, subcutaneous injection, Recombinant human granulocyte colony-stimulating factor: 5 μg\u002Fkg on days 0-8; discontinue if WBC \\> 20 × 10⁹\u002FL;",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Venetoclax,Azacitidine,Arubicin,Cytarabine,G-CSF.","Specific Medication for the VACAG Protocol:\n\n1. Two-week regimen group Azacitidine: 75 mg\u002Fm² on days 1-7 by subcutaneous injection, Venetoclax: 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-14, oral, Arubicin: 12-14 mg\u002Fm² on days 1, 3, 5, and 7 (IV infusion), Cytarabine: 10 mg\u002Fm² every 12 hours on days 1-7, subcutaneous injection, G-CSF: 5 μg\u002Fkg on days 0-8; discontinue if WBC \\> 20 × 10⁹\u002FL;\n2. Three-week regimen group Venetoclax administered for 21 days; dosage and administration are the same as in the 2-week regimen group.",[9,15],null,[27],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Wang sanbin","CONTACT","13187424131","1739701184@qq.com",{"type":33,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100643248","phase-2-va-cag-two-week-vs-three-week-regimen-for-induction-remission-in-newly-diagnosed-acute-myeloid-leukemia-100643248",false,"NCT07642453","VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia.","VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Diagnosis of acute myeloid leukemia confirmed according to NCCN guidelines;\n2. Age 18-75 years;\n3. Body weight 30-100 kg;\n4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3;\n5. No significant organ dysfunction (echocardiographic ejection fraction \\>45%; bilirubin \\\u003C2 times the upper limit of normal; AST and ALT \\\u003C3 times the upper limit of normal; serum creatinine \\\u003C2 times the upper limit of normal);\n6. No severe infections;\n7. Study participants voluntarily agree to participate in this clinical trial and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with other types of diseases;\n2. Patients with a projected survival of less than 1 month;\n3. History of prior treatment;\n4. Severe psychiatric or neurological disorders that impair the ability to provide informed consent and\u002For report or observe adverse events;\n5. Other circumstances deemed unsuitable for enrollment by the investigator.","ALL","18 Years","75 Years",{"count":45,"type":46},110,"ESTIMATED","INTERVENTIONAL",[49],"PHASE2","Objective: This clinical trial aims to compare the efficacy and safety of the VA-CAG regimen administered as a two-week schedule versus a three-week schedule for induction remission in acute myeloid leukemia (AML).\n\nKey Research Questions:\n\n1. Is the efficacy of the two-week VA-CAG regimen equivalent to that of the three-week regimen in inducing remission in AML?\n2. Does the two-week VA-CAG regimen reduce treatment-related adverse events compared to the three-week regimen? Methods: Researchers will compare the efficacy and safety of the two-week VA-CAG regimen with the three-week regimen for induction remission in AML. Study participants will be randomly assigned to receive standard treatment with either the two-week or three-week VA-CAG regimen. Patients are required to attend monthly follow-up visits for a total of one year. At each follow-up, the following assessments will be performed: complete blood count, liver and kidney function tests, bone marrow aspiration, flow cytometric measurement of minimal residual disease (MRD), and\u002For fusion gene analysis, along with monitoring of other efficacy endpoints and adverse reactions.",[52],"Acute Myeloid Leukemia (AML)","NOT_YET_RECRUITING","2026-06-07",{"date":56,"type":57},"2026-06-11","ACTUAL",{"date":59,"type":46},"2026-06-01",{"date":61,"type":46},"2028-06-01",{"name":5,"class":6}]